

## Summary of Product Characteristics

### 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Cardisure flavoured 1.25 mg Tablets For dogs

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 tablet contains:

**Active substance:**

Pimobendan 1.25 mg

**Excipients:**

For the full list of excipients, see section 6.1.

### 3 PHARMACEUTICAL FORM

Tablet.

Light brown, round tablets, scored on one side and plain on the other side.

The tablets can be divided into 2 equal parts.

### 4 CLINICAL PARTICULARS

#### 4.1 Target Species

Dogs

#### 4.2 Indications for use, specifying the target species

For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

#### 4.3 Contraindications

Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).

See also section 4.7.

#### 4.4 Special warnings for each target species

The product should be administered on an empty stomach at least one hour before meals, as absorption is reduced when given with feed.

## 4.5 Special precautions for use

### Special precautions for use in animals

The product is flavoured. To avoid accidental ingestion the tablets should be stored out of reach of dogs. An *in vitro* study in rat tissue demonstrated that pimobendan increased glucose-induced insulin release from pancreatic  $\beta$ -cells in a dose-dependent manner. If the product is administered to diabetic dogs, blood glucose levels should be carefully monitored.

As pimobendan is metabolised in the liver, particular care should be taken when administering the product to dogs with severe hepatic insufficiency.

Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan. (See also section 4.6).

### Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

## 4.6 Adverse reactions (frequency and seriousness)

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed.

Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn.

In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

## 4.7 Use during pregnancy, lactation or lay

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic or foetotoxic effects. However, these studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and have also shown that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian.

## 4.8 Interaction with other medicinal products and other forms of interaction

In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the  $\beta$ -antagonist propranolol.

#### 4.9 Amounts to be administered and administration route

Do not exceed the recommended dosage.

Determine the body weight accurately before treatment to ensure correct dosage.

The tablets should be administered orally at a dose range of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg body weight. The dose should be divided into two administrations (0.25 mg/kg body weight each), one half of the dose in the morning and the other half approximately 12 hours later. The maintenance dose should be individually adjusted by the responsible veterinarian according to the severity of the disease.

The product may be combined with a diuretic treatment, e.g. furosemide.

To break a tablet into two halves, place the tablet on an even surface with the scored side up, hold one half of the tablet and press down on the other half.



Each dose should be given approximately one hour before feeding.

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In the case of overdose, a positive chronotropic effect and vomiting may occur. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

In prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose, mitral valve thickening and left ventricular hypertrophy were observed in some dogs.

#### 4.11 Withdrawal Period(s)

Not applicable.

### 5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Cardiac stimulant (phosphodiesterase inhibitor).

ATCvet code: QC01CE90

## 5.1 Pharmacodynamic properties

Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.

Pimobendan exerts its stimulatory myocardial effect by a dual mode of action: it increases calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). It also exhibits a vasodilatory action through inhibition of phosphodiesterase III activity.

When used in cases of valvular insufficiency in conjunction with furosemide, the product has been shown to improve the quality of life and extend life expectancy in treated dogs.

When used in a limited number of cases of dilated cardiomyopathy in conjunction with furosemide, enalapril and digoxin the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.

## 5.2 Pharmacokinetic properties

### Absorption:

Following oral administration of this veterinary medicinal product the absolute bio-availability of the active principle is 60 - 63 %. Since this bio-availability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.

### Distribution:

The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.

### Metabolism:

The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG-212, in essence glucuronides and sulphates.

### Elimination:

The plasma elimination half-life of pimobendan is  $1.1 \pm 0.7$  hours. The main active metabolite is eliminated with a plasma elimination half-life of  $1.5 \pm 0.2$  hours. Almost the entire dose is eliminated via faeces.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Cellulose, microcrystalline  
Croscarmellose sodium  
Magnesium stearate  
Natural meat flavour

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf life of divided tablets after first opening the blister: 3 days.

## **6.4 Special precautions for storage**

Do not store above 30 °C.

Return any divided tablet to the opened blister and use within 3 days.

## **6.5 Nature and composition of immediate packaging**

Aluminium – PVC/PE/PVDC blister:

10 tablets per blister: 2, 5, 10 or 25 blisters per carton.

Aluminium – Aluminium blister:

10 tablets per blister: 2, 5, 10 or 25 blisters per carton.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Eurovet Animal Health BV

Handelsweg 25

5531 AE Bladel

The Netherlands

## **8 MARKETING AUTHORISATION NUMBER(S)**

VPA 10989/059/001

## **9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 22<sup>nd</sup> July 2011

Date of last renewal: 8<sup>th</sup> July 2016

## **10 DATE OF REVISION OF THE TEXT**